CTOs on the Move

Southmedic

www.southmedic.com

 
Established in 1983 Southmedics Domestic Division is one of the largest independent distributors of operating room products in Canada with a dynamic and efficient sales force from coast to coast. We specialize in selling surgical and specialty operati...
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

Syntiron

Syntiron LLC is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

KESIN PHARMA

Kesin Pharma is a specialty pharmaceutical company that offers a variety of products, including unit dose drug repackaging for liquid medications and creams/ointments.

Marker Therapeutics

We are a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker`s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. Once infused into patients, this population of T cells attacks multiple tumor targets and acts to activate the patient`s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less expensive and easier to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling therapeutic product profile, as compared to current gene-modified CAR-T and TCR-based therapies. Marker is also advancing a number of innovative peptide- and gene-based immuno-therapeutics for the treatment of cancer and metastatic disease, including our Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and our HER2/neu+ peptide antigen program (TPIV100/110) in Phase II clinical trials. In parallel, we are developing a proprietary DNA expression technology named PolyStartâ„¢ to improve the ability of the cellular immune system to recognize and destroy diseased cells.

ReCept Pharmacy

ReCept Pharmacy is a Fort Worth, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Salix

Salix is committed to being the leading US specialty pharmaceutical company licensing, developing, and marketing innovative products to healthcare professionals to treat gastrointestinal disorders in patients.